Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: eren n. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
The Longitudinal Evolution of Post-COVID-19 Outcomes Among Hemodialysis Patients in Turkey.
Ozturk S, Turgutalp K, Arici M, Gorgulu N, Tonbul HZ, Eren N, Gencer V, Ayli MD, Pembegul I, Dolarslan ME, Ural Z, Colak H, Ozler TE, Can O, Demir ME, Altunoren O, Huddam B, Onec K, Demirelli B, Aydin Z, Altun E, Alagoz S, Ayar Y, Eser ZE, Berktas B, Yilmaz Z, Ates EU, Yuksel E, Sahin GK, Aktar M, Cebeci E, Dursun B, Kocak SY, Yildiz A, Kazan S, Gok M, Sengul E, Tugcu M, Ozturk R, Kahvecioglu S, Kara E, Kaya B, Sahin G, Sakaci T, Sipahi S, Kurultak I, Durak BA, Altiparmak MR, Ecder SA, Karadag S, Dincer MT, Ozer H, Bek SG, Ulu MS, Gungor O, Bakir EA, Odabas AR, Seyahi N, Yildiz A, Ates K. Ozturk S, et al. Among authors: eren n. Kidney Int Rep. 2022 Jun;7(6):1393-1405. doi: 10.1016/j.ekir.2022.03.017. Epub 2022 Mar 25. Kidney Int Rep. 2022. PMID: 35350104 Free PMC article.
Thirst intensity survey in ADPKD patients.
Gocay Bek SG, Yıldız N, Islam M, Ergul M, Sarıoglu I, Guven Taymez D, Eren N, Uslu H, Tosun M, Dervisoglu E, Kalender B, Balcı S, Waldreus N. Gocay Bek SG, et al. Among authors: eren n. Clin Exp Nephrol. 2023 Oct;27(10):819-827. doi: 10.1007/s10157-023-02373-7. Epub 2023 Jun 23. Clin Exp Nephrol. 2023. PMID: 37351680
Correction to: Thirst intensity survey in ADPKD patients.
Bek SG, Yıldız N, Islam M, Ergul M, Sarıoglu I, Guven Taymez D, Eren N, Uslu H, Tosun M, Dervisoglu E, Kalender B, Balcı S, Waldreus N. Bek SG, et al. Among authors: eren n. Clin Exp Nephrol. 2023 Oct;27(10):828. doi: 10.1007/s10157-023-02375-5. Clin Exp Nephrol. 2023. PMID: 37428290 No abstract available.
Is Nebivolol Really Effective in Preventing Contrast Induced Nephropathy?
Altunoren O, Balli M, Eren N, Tasolar H, Arpaci A, Caglayan CE, Yavuz YC, Gungor O. Altunoren O, et al. Among authors: eren n. Kidney Blood Press Res. 2015;40(5):533-41. doi: 10.1159/000368529. Epub 2015 Oct 25. Kidney Blood Press Res. 2015. PMID: 26496491 Free article.
Renal Tubular Acidosis in Patients with Systemic Lupus Erythematosus.
Eren N, Gungor O, Sarisik FN, Sokmen F, Tutuncu D, Cetin GY, Yazici A, Gökçay Bek S, Altun E, Altunoren O, Cefle A. Eren N, et al. Kidney Blood Press Res. 2020;45(6):883-889. doi: 10.1159/000509841. Epub 2020 Oct 27. Kidney Blood Press Res. 2020. PMID: 33108786 Free article.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?
Cetinkaya H, Gursu M, Yazici H, Cebeci E, Eren N, Altiparmak MR, Akcay OF, Sahin G, Dheir H, Basturk T, Atilgan KG, Aydemir N, Turgutalp K, Yilmaz M, Sirali SK, Tatar E, Boz EG, Mirioglu S, Kazan S, Aydin E, Aydin Z, Turkmen K, Kutlay S, Karagoz F, Ogutmen MB, Ozturk S, Ozkan O, Yildiz N, Dincer T, Yasar E, Gok M, Turkmen A, Dede F, Derici U. Cetinkaya H, et al. Among authors: eren n. J Nephrol. 2023 Nov 10. doi: 10.1007/s40620-023-01770-1. Online ahead of print. J Nephrol. 2023. PMID: 37947938
Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group.
Oruc A, Sumnu A, Turkmen A, Basturk T, Cebeci E, Turgutalp K, Cetinkaya H, Uzerk Kibar M, Seyahi N, Tatar E, Ergul M, Derici Ü, Aylı MD, Pınar M, Bakar B, Kazancıoglu R, Yıldız A, Dirim AB, Yılmaz Z, Turkmen K, Tunca O, Koc M, Kutlay S, Micozkadıoglu H, Azak A, Boztepe B, Ustundag S, Şafak Ozturk S, Unsal A, Karadag S, Sahin G, Yenigun EC, Eren N, Gullulu M, Gursu M, Ozturk S. Oruc A, et al. Among authors: eren n. Ren Fail. 2024 Dec;46(1):2341787. doi: 10.1080/0886022X.2024.2341787. Epub 2024 Apr 18. Ren Fail. 2024. PMID: 38637275 Free PMC article.
194 results